PHARMACEUTICALS News & Analysis

We think a delay rather than an outright rejection for this company’s product is the likelier outcome, but the shares still look expensive.

We assume that pharmaceutical tariffs will be enacted. While this could bring short-term margin pressure, we have not changed our valuations.